Moreover, it is accepted that sensitive EGFR mutation predicts benefit from EGFR-TKIs treatment and even from chemotherapy in NSCLC [8, 9, 18, 19, 26, 32-34]. Here, EGFR is linked to non-small cell lung carcinoma.